- Home
- WATT vs ENVB Comparison
WATT vs ENVB Comparison
Compare WATT & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- ENVB
- Stock Information
- Founded
- WATT 2012
- ENVB 1994
- Country
- WATT United States
- ENVB United States
- Employees
- WATT N/A
- ENVB N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- ENVB Health Care
- Exchange
- WATT Nasdaq
- ENVB Nasdaq
- Market Cap
- WATT 3.9M
- ENVB 4.4M
- IPO Year
- WATT 2014
- ENVB N/A
- Fundamental
- Price
- WATT $0.61
- ENVB $0.54
- Analyst Decision
- WATT Strong Buy
- ENVB Strong Buy
- Analyst Count
- WATT 2
- ENVB 1
- Target Price
- WATT $2.25
- ENVB $10.00
- AVG Volume (30 Days)
- WATT 133.2K
- ENVB 1.3M
- Earning Date
- WATT 11-07-2024
- ENVB 11-11-2024
- Dividend Yield
- WATT N/A
- ENVB N/A
- EPS Growth
- WATT N/A
- ENVB N/A
- EPS
- WATT N/A
- ENVB N/A
- Revenue
- WATT $370,184.00
- ENVB N/A
- Revenue This Year
- WATT $95.75
- ENVB N/A
- Revenue Next Year
- WATT $834.07
- ENVB N/A
- P/E Ratio
- WATT N/A
- ENVB N/A
- Revenue Growth
- WATT N/A
- ENVB N/A
- 52 Week Low
- WATT $0.54
- ENVB $0.36
- 52 Week High
- WATT $2.75
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- WATT 48.13
- ENVB 62.70
- Support Level
- WATT $0.56
- ENVB $0.44
- Resistance Level
- WATT $0.61
- ENVB $0.49
- Average True Range (ATR)
- WATT 0.04
- ENVB 0.04
- MACD
- WATT 0.01
- ENVB 0.01
- Stochastic Oscillator
- WATT 69.60
- ENVB 93.00
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.